These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26572686)

  • 1. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    Foster GR; Ferenci P; Asselah T; Mantry P; Dufour JF; Bourlière M; Forton D; Maevskaya M; Wright D; Yoshida EM; García-Samaniego J; Oliveira C; Wright M; Warner N; Sha N; Quinson AM; Stern JO
    J Viral Hepat; 2016 Mar; 23(3):227-31. PubMed ID: 26572686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
    Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
    J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
    Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
    AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
    World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
    Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
    Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
    Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
    Nishiguchi S; Sakai Y; Kuboki M; Tsunematsu S; Urano Y; Sakamoto W; Tsuda Y; Steinmann G; Omata M
    Liver Int; 2014 Jan; 34(1):78-88. PubMed ID: 23944720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
    Sulkowski MS; Asselah T; Lalezari J; Ferenci P; Fainboim H; Leggett B; Bessone F; Mauss S; Heo J; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
    Hepatology; 2013 Jun; 57(6):2143-54. PubMed ID: 23359516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
    Zeuzem S; Mantry P; Soriano V; Buynak RJ; Dufour JF; Pockros PJ; Wright D; Angus P; Buti M; Stern JO; Kadus W; Vinisko R; Böcher W; Mensa FJ
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):923-6. PubMed ID: 27140229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
    Sulkowski MS; Bourlière M; Bronowicki JP; Asselah T; Pawlotsky JM; Shafran SD; Pol S; Mauss S; Larrey D; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
    Hepatology; 2013 Jun; 57(6):2155-63. PubMed ID: 23504636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
    Tatum H; Thuluvath PJ; Lawitz E; Martorell C; DeMicco M; Cohen S; Rustgi V; Ravendhran N; Ghalib R; Hanson J; Zamparo J; Zhao J; Cooney E; Treitel M; Hughes E
    J Viral Hepat; 2015 Aug; 22(8):658-64. PubMed ID: 25496007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
    Zeuzem S; Berg T; Gane E; Ferenci P; Foster GR; Fried MW; Hezode C; Hirschfield GM; Jacobson I; Nikitin I; Pockros PJ; Poordad F; Scott J; Lenz O; Peeters M; Sekar V; De Smedt G; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Feb; 146(2):430-41.e6. PubMed ID: 24184810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
    Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
    J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
    Gane EJ; DeJesus E; Janczewska E; George J; Diago M; Da Silva MH; Reesink H; Nikitin I; Hinrichsen H; Bourgeois S; Ferenci P; Shukla U; Kalmeijer R; Lenz O; Fevery B; Corbett C; Beumont M; Jessner W
    BMC Infect Dis; 2017 Jun; 17(1):389. PubMed ID: 28577353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.